Pharma & biotech

First patient has received Ferring's gene therapy for bladder cancer

The pharmaceutical company does not yet have full production capacity, so only selected patients will initially get access to the gene therapy which is the first of its kind.
A 78-year-old American man is the first to be treated with the gene therapy Adstiladrin, developed by Ferring Pharmaceuticals and approved by the US Food and Drug Administration in December 2022. | Photo: Ferring / Pr
A 78-year-old American man is the first to be treated with the gene therapy Adstiladrin, developed by Ferring Pharmaceuticals and approved by the US Food and Drug Administration in December 2022. | Photo: Ferring / Pr
by ALBERT RØNNING-ANDERSSON

A 78-year-old American man can proudly claim to be the first person to receive treatment with the only gene therapy available for bladder cancer on the market: Adstiladrin, developed by Ferring Pharmaceuticals.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs